📊 CTMX Key Takeaways
Investment Thesis
CytomX Therapeutics exhibits severe financial distress with negative net income of -$17.4M despite $76.2M in revenue, indicating fundamental operational unprofitability in the pharmaceutical sector. The company is burning cash at an alarming rate with -$75.8M free cash flow, and at current cash levels ($12.7M) faces a critical runway crisis within months without significant capital raises or operational turnaround.
CTMX Strengths
- Strong liquidity position with 3.09x current ratio providing near-term operational flexibility
- Low leverage with 0.02x debt-to-equity ratio minimizing financial distress from debt obligations
- Flat revenue maintenance at $76.2M suggests some stability in core business despite unprofitability
CTMX Risks
- Catastrophic operating cash burn of -$75.6M annually with only $12.7M cash reserves indicates potential insolvency within 2 months without external funding
- Persistent negative net margins of -22.8% and operating margins of -29.3% demonstrate structural unprofitability across the business model
- Operating income deterioration with -$22.4M loss despite revenue stability indicates inability to scale operations profitably or control costs effectively
Key Metrics to Watch
- Operating cash flow trajectory and monthly burn rate to assess runway duration
- Revenue growth acceleration and cost structure improvements to achieve positive operating leverage
- Cash balance and availability of financing or partnership deals to address immediate liquidity crisis
CTMX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.09x current ratio provides a solid financial cushion.
CTMX Profitability Ratios
CTMX vs Healthcare Sector
How CytomX Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CTMX Balance Sheet & Liquidity
CTMX 5-Year Financial Trend
5-Year Trend Summary: CytomX Therapeutics, Inc.'s revenue has grown significantly by 38% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.38 reflects profitable operations.
CTMX Growth Metrics (YoY)
CTMX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $6.0M | -$154.0K | $0.07 |
| Q2 2025 | $18.7M | -$154.0K | $0.00 |
| Q1 2025 | $41.5M | $13.8M | $0.17 |
| Q3 2024 | $26.4M | -$1.1M | $-0.02 |
| Q2 2024 | $24.7M | -$1.1M | $-0.02 |
| Q1 2024 | $23.5M | -$3.3M | $-0.05 |
| Q3 2023 | $11.1M | -$1.1M | $-0.02 |
| Q2 2023 | $12.9M | -$1.1M | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CTMX Capital Allocation
CTMX SEC Filings
Access official SEC EDGAR filings for CytomX Therapeutics, Inc. (CIK: 0001501989)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CTMX
What is the AI rating for CTMX?
CytomX Therapeutics, Inc. (CTMX) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CTMX's key strengths?
Strong liquidity position with 3.09x current ratio providing near-term operational flexibility. Low leverage with 0.02x debt-to-equity ratio minimizing financial distress from debt obligations.
What are the risks of investing in CTMX?
Catastrophic operating cash burn of -$75.6M annually with only $12.7M cash reserves indicates potential insolvency within 2 months without external funding. Persistent negative net margins of -22.8% and operating margins of -29.3% demonstrate structural unprofitability across the business model.
What is CTMX's revenue and growth?
CytomX Therapeutics, Inc. reported revenue of $76.2M.
Does CTMX pay dividends?
CytomX Therapeutics, Inc. does not currently pay dividends.
Where can I find CTMX SEC filings?
Official SEC filings for CytomX Therapeutics, Inc. (CIK: 0001501989) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CTMX's EPS?
CytomX Therapeutics, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.